Skip to main content
Transgene logo

Transgene — Investor Relations & Filings

Ticker · TNG ISIN · FR0005175080 LEI · 969500PDJW8N0FSGGK69 PA Professional, scientific and technical activities
Open in API
Filings indexed 796 across all filing types
Latest filing 2022-11-07 Interim / Quarterly Rep…
Country FR France
Listing PA TNG

About Transgene

https://www.transgene.fr/en/

Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.

Recent filings

Filing Released Lang Actions
Inside Information / News release on accounts, results
Interim / Quarterly Report Classification · 1% confidence The document is a business update and financial position report for the third quarter of 2022. It contains substantive financial data (operating income, cash position, revenue breakdown) and detailed operational updates on clinical trials. It is not a full annual report (10-K) nor a simple announcement of a report (RPA), but rather a comprehensive interim financial and operational update, which fits the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-07 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is a quarterly business and financial update from Transgene (a biotechnology company). It provides a summary of clinical trial progress, R&D highlights, and a table of financial figures (revenues and research funding) for the third quarter of 2022. While it contains financial data, it is a narrative update rather than a full statutory interim financial report. In the context of financial reporting, this type of document, which provides a periodic update on business activities and financial highlights, is classified as an Earnings Release (ER). Q3 2022
2022-11-07 French
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a press release from Transgene announcing positive interim analysis results from a Phase II clinical trial (TG4001 + Avelumab) and scheduling a webcast presentation for investors and analysts. It details clinical trial progress, endpoints, and future plans. This type of announcement, focusing on key results and scheduling a call to discuss them, is characteristic of an Earnings Release (ER) or a general press release related to operational/clinical updates. Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is an announcement of results rather than just a notice of a report publication (RPA), the most fitting category for a clinical/operational update announcing key findings is the Earnings Release (ER) category, as these often include operational highlights alongside financial ones, or it falls under a general announcement. Given the focus on clinical trial results and the scheduling of an investor call, it strongly aligns with the function of an Earnings Release (ER) which communicates period results/updates to the market, even if the results are clinical rather than purely financial. It is not a formal regulatory filing like 10-K or IR, nor is it a proxy statement or dividend notice. It is a direct communication of material operational news. H1 2024
2022-11-02 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release dated November 2, 2022, announcing positive interim results from a Phase II clinical trial (TG4001 + Avelumab) for HPV-positive cancers. It details the trial's continuation, patient numbers, primary endpoints (PFS), and includes management commentary and conference call details. This content structure—announcing key clinical trial updates, often including interim efficacy data and future plans—is characteristic of an Earnings Release (ER) or a general press release related to operational/clinical progress. Since it focuses on the immediate release of key financial/clinical milestones rather than a comprehensive periodic report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate fit, as clinical trial updates often accompany or substitute for traditional earnings highlights in biotech/pharma. It is not a full transcript (CT), a formal annual report (10-K), or a simple announcement of a report publication (RPA). FY 2022
2022-11-02 French
Inside Information / Other news releases
Investor Presentation Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces an "R&D Day: Presentations to Highlight Transgene's Competitive Positioning...". It details the agenda, speakers, and topics to be covered during this specific investor/analyst event. This type of material, which presents scientific updates, clinical data highlights, and strategic outlooks in a presentation format intended for investors, aligns best with the Investor Presentation (IP) category. While it is a press release, its core function is to disseminate the content of the investor presentation event, making IP more specific than a general Regulatory Filing (RNS) or Earnings Release (ER). It is not a full financial report (10-K or IR) or a transcript (CT).
2022-09-27 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces an 'R&D Day' event where the company will present updates on its competitive positioning, new immunotherapies, and updated clinical data (TG4001, TG4050, Invir.IO™ platform). It includes commentary from the CEO, details of presentations by external experts, and links to the live webcast and presentation materials. This structure—announcing an event where presentations will be given, rather than being the presentation itself or a formal regulatory filing like a 10-K or ER—strongly suggests it is an announcement intended for investors and analysts about upcoming information dissemination. Since it is an announcement about an event where investor presentations will occur, it aligns best with the Investor Presentation (IP) category, as the content discussed is precisely what would be in an investor presentation, even though this specific document is the announcement of that event. However, given the options, the content is a detailed update on strategy and clinical pipeline, which is the core of an Investor Presentation (IP). It is not a short announcement of a report (RPA/RNS), as it contains substantial detail about the content of the R&D day itself. It is more specific than a general Regulatory Filing (RNS).
2022-09-27 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.